This content is not available in your region. 


Esse conteúdo do nosso site está disponível apenas em inglês

EU approves Chr. Hansen’s unique triple strain probiotic for poultry

GALLIPRO® Fit probiotic ready for EU market after approval from European Commission

Jan 18. 2021 15:34 GTM

Following a previous positive opinion from EFSA (European Food Safety Agency), GALLIPRO® Fit probiotic has now been approved for sale in the EU by the European Commission. GALLIPRO® Fit was first successfully launched in the US in 2017, followed by Australia in 2018 and the South African and Asian markets in 2019.

“We are really excited to get this approval after research data and field trials have documented the efficacy and safety of GALLIPRO® Fit. We see it as an official blue stamp of our probiotic solution for some of the poultry industry’s biggest challenges that customers in other parts of the world have benefitted from since 2017,” says Dorthe Sandvang, DVM, PhD, from Chr. Hansen’s Animal Health Innovation.

“GALLIPRO® Fit is the trademark for Chr. Hansen’s first probiotic to combine three unique strains in one product to address some of the key challenges faced by poultry producers today. Together, the three novel strains in GALLIPRO® Fit have been proven to effectively support the digestive performance and a healthy normal immune system in broilers, pullet layers/breeders and turkeys. At the same time, it brings production profitability,” she elaborates.

 

Success around the world 

With the registration and regulatory approval secured in Europe, Chr. Hansen is now able to bring the successful product to a new region – and is also preparing for a launch in a new EMEA markets in 2021.

“Over the past years we have witnessed a very positive adoption of GALLIPRO® Fit by customers in the US, Australia, Asia and South Africa. We can’t wait to bring this highly relevant solution to European and other EMEA markets,” says Christophe Bostvironnois, senior global product manager for Poultry at Chr. Hansen.

GALLIPRO® Fit has been proven to be effective in the following key areas:

  • Boosts husbandry management by supporting normal physiological functions
  • Contributes to food safety
  • Risk reduction of failure with specific laboratory assays

With feed representing 68% of the cost of broiler production1, production profitability is important, and margins are under pressure. 

Protecting poultry from Clostridium perfringens, Salmonella and Escherichia coli is key for farmers to get the highest productivity for their chickens. In 2019, 1 in 3 outbreaks of foodborne disease was due to Salmonella.  Poland, Spain and Slovakia reported the highest rate of Salmonella outbreaks that year.2 Also, uncontrolled clostridiosis in production systems can cost more than 0.05 €/ bird.3

GALLIPRO® Fit contains unique strains of bacteria that are selected for their relative effectiveness at demonstrating beneficial modes of action, making them particularly suitable for improving the success of commercial poultry operations.

“From our library of bacterial strains, we carefully select strains with a research-proven ability to influence animal welfare, support a normal immune system and keep birds healthier. With GALLIPRO® Fit we are bringing a tried and tested solution to help European poultry farmers protect their business,” concludes Bostvironnois.

 

 

References
1 Wageningen UR 2014
2 Wattagnet
3 Poultry world 2018 



GALLIPRO® Fit is a trademark of Chr. Hansen A/S

 

A Chr. Hansen é uma empresa de biociência global e diferenciada, que desenvolve soluções com ingredientes naturais para as indústrias alimentícia, nutricional, farmacêutica e agrícola. Na Chr. Hansen, estamos em uma posição privilegiada para impulsionar mudanças positivas por meio de nossas soluções microbianas. Há mais de 145 anos, nós trabalhamos para possibilitar uma agricultura sustentável, rótulos mais limpos e uma vida mais saudável para mais pessoas em todo o mundo. Nossas plataformas de tecnologia microbiana e de fermentação, que incluem nossa ampla e relevante coleção de cerca de 40 mil cepas microbianas, têm um potencial revolucionário. Atendendo às necessidades dos clientes e às tendências globais, nós continuamos a desbloquear o poder das bactérias boas para dar resposta aos desafios globais, como o desperdício de alimentos, a saúde global e o uso excessivo de pesticidas e antibióticos. Como sendo a empresa de biotecnologia mais sustentável do mundo, nós tocamos a vida de mais de 1 bilhão de pessoas todos os dias. Impulsionados por nosso legado de inovação e curiosidade pela ciência pioneira, nosso objetivo – “To grow a better world. Naturally.” – está no centro de tudo que fazemos.


Compartilhe